SCHEMBL30829596

SCHEMBL30829596

COc1cccc2ncc(C(=O)O)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.51
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
MRGPRX4 Q96LA9 2/20 0.46
CDC25B P30305 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30440820 1.00 MGAM (0.51) MGAMPDGFRBPDGFRAHSD17B10KDM4E
SCHEMBL2202272 1.00 MGAM (0.51) MGAMPDGFRBPDGFRAHSD17B10KDM4E
SCHEMBL4404909 0.88 RXFP1 (0.46) HSD17B10ALDH1A1PDE3BPDE3ASMN1; SMN2
SCHEMBL19329127 0.87 HPGDS (0.52) HSD17B10KDM4ESMN1; SMN2L3MBTL1HPGDS
SCHEMBL2201313 0.87 ALPL (0.47) HSD17B10KDM4EALDH1A1HPGDALOX15
SCHEMBL4137438 0.84 ACACB (0.44) PDGFRBPDGFRAHSD17B10KDM4EALDH1A1
SCHEMBL2199970 0.82 PDGFRB (0.52) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL2199929 0.80 MRGPRX4 (0.56) MGAMHPGDMRGPRX4SMN1; SMN2RXRA
SCHEMBL9353615 0.80 MGAM (0.56) MGAMHSD17B10KDM4EALDH1A1HPGD
SCHEMBL27909234 0.78 PDE10A (0.52) HSD17B10KDM4EALDH1A1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB MGAM 3707/4885PDGFRB 838/4885PDGFRA 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.